Ultimovacs previously already hinted at a dash to preserve cash following the failure of its cancer vaccine in a phase 2 trial.
Bristol Myers` Opdivo-Yervoy combo meets main goal in liver cancer trial
Ultimovacs Announces Results from INITIUM Study Evaluating UV1 Vaccination
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
BMS`s Opdivo-Yervoy excels in first-line colorectal cancer trial
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
Neoadjuvant treatment with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) led to responses and was well tolerated in patients with resectable hepatocellular carcinoma (HCC), according to a preliminary analysis of the phase 1b PRIME-HCC trial (NCT03682276) presented at the 2023 International Liver Cancer Association Conference.
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster cancer immunotherapies.